Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Updates on DREAMM-2

Sagar Lonial • 19 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Carfilzomib Daratumumab Pomalidomide
DREAMM-2

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, gives an update on DREAMM-2, evaluating single-agent belantamab mafodotin in relapsed/refractory multiple myeloma. Furthermore, Dr Lonial highlights the 11-month duration of response seen in the 2.5mg/kg cohort. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sagar Lonial

Practical advice for physicians treating patients with myeloma using belantamab mafodotin 0:37
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial • 16 May 2025
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development 1:08
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Sagar Lonial • 16 May 2025
The ideal trial on the road to achieving the best outcome for patients with myeloma 0:41
The ideal trial on the road to achieving the best outcome for patients with myeloma
Sagar Lonial • 16 May 2025
The potential of CELMoDs for the treatment of multiple myeloma 0:50
The potential of CELMoDs for the treatment of multiple myeloma
Sagar Lonial • 16 May 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals